For research use only
| Cat No. | ABC-TC5559 |
| Product Type | Human Lymphoma Cell Lines |
| Cell Type | Lymphoblastoid |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymphoma |
| Disease | Anaplastic Large Cell Lymphoma |
| Product Code | KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299 |
KARPAS 299 cells, T-cell lymphoma with t(2;5) translocation, express CD30 and ALK proteins, growing in suspension and forming xenograft tumors rapidly.
KARPAS 299 is a human T-cell lymphoma cell line established in 1986 from the peripheral blood of a 25-year-old Caucasian male diagnosed with T-cell non-Hodgkin’s lymphoma, now classified as CD30⁺ anaplastic large cell lymphoma (ALCL) . The cells exhibit a lymphoblastoid morphology and grow in suspension as single cells or small clusters, with a doubling time of approximately 30 hours. KARPAS 299 cells exhibit a hypodiploid karyotype (44-45 chromosomes) with the pathognomonic t(2;5)(p23;q35) translocation that generates the NPM-ALK fusion oncogene, a defining feature of ALK-positive anaplastic large cell lymphoma (ALCL). While the line maintains expression of some T-cell markers including CD4 and CD7, it lacks surface CD3 (a key T-cell receptor component) and CD2, consistent with its classification as a mature T-cell neoplasm. The cells strongly express CD30 (Ki-1 antigen) and ALK protein, hallmarks of systemic ALCL. KARPAS 299 reliably forms tumors in immunodeficient mice upon subcutaneous inoculation, retaining these characteristic markers in xenografts, which has established it as a gold-standard model for investigating ALCL pathogenesis and evaluating CD30-directed therapies like brentuximab vedotin.
| Product Code | KARPAS-299; Karpas 299; KARPAS 299; Karpas299; KARPAS299; K299 |
| Species | Human |
| Cat.No | ABC-TC5559 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphoblastoid |
| Growth Mode | Suspension |
| Shipping Info | Dry ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lymphoma |
| Disease | Anaplastic Large Cell Lymphoma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
KARPAS 299 is a critical tool in lymphoma research, widely used to explore the molecular mechanisms of the t(2;5) translocation and the oncogenic activity of the NPM-ALK fusion protein. It is particularly valuable for characterizing CD30-positive large cell lymphomas and dissecting the signaling pathways involved in ALCL pathogenesis. This cell line supports the development and testing of targeted therapies, especially those aimed at ALK and CD30, such as monoclonal antibodies and small-molecule inhibitors. Its utility in xenograft models further enhances its relevance in translational research and therapeutic discovery for aggressive T-cell lymphomas.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
